Idiopathic Pulmonary Fibrosis Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2017-30) in the 7MM

Idiopathic Pulmonary Fibrosis Treatment Market, Epidemiology, Emerging Therapies and Key Companies Working in the Domain During the Study Period (2017-30) in the 7MM

“Idiopathic Pulmonary Fibrosis Market”
The Idiopathic Pulmonary Fibrosis market size is anticipated to increase due to the launch of the upcoming therapies such as Pamrevlumab, RG6354, Ziritaxestat, and others during the forecast period (2020-30).

DelveInsight’s Idiopathic Pulmonary Fibrosis market report offers comprehensive coverage of the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Idiopathic Pulmonary Fibrosis (IPF) from 2017 to 2030 segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).

Some of the Key Highlights from the Idiopathic Pulmonary Fibrosis Market Report

  • According to DelveInsight’s, Idiopathic Pulmonary Fibrosis epidemiology insights, the total prevalent population was estimated to be 230,123 in the 7MM in 2020.

  • The United States accounted for the highest Idiopathic Pulmonary Fibrosis prevalent population among the 7MM in 2020. Out of which the highest IPF cases were reported in the males as compared to the females.

  • Among the EU5 countries, the UK has the highest IPF population while France had the lowest in 2020.

  • Some of the major players in the global Idiopathic Pulmonary Fibrosis treatment market in the late phase of clinical development are FibroGen, Roche, Galapagos NV, MediciNova, Galecto Biotech, and others. 

  • Key pipeline therapies in the Idiopathic Pulmonary Fibrosis market include Pamrevlumab, RG6354, Ziritaxestat, Tipelukast, GB 0139, and several others that are anticipated to enter the IPF market in the upcoming years. 

  • FibroGen is developing Pamrevlumab (also known as FG-3019), a first-in-class, a completely humanized monoclonal antibody that suppresses the function of connective tissue growth factor (CTGF), a key mediator in the advancement of fibrosis and other related disorders. It is also being researched for pancreatic cancer and Duchenne muscular dystrophy (DMD) in Phase II developmental stage.

  • RG6354 (PRM-151) which is being developed by Roche is a recombinant human serum amyloid P/pentraxin 2 protein (PTX2) that is administered intravenously.

Request for a sample to get complete detail on the disease causes, diagnosis, and treatment @ Treatment for Idiopathic Pulmonary Fibrosis

The Idiopathic Pulmonary Fibrosis market report also covers current treatment practices/algorithms, Idiopathic Pulmonary Fibrosis market drivers, Idiopathic Pulmonary Fibrosis market barriers, and unmet medical needs in order to curate the best opportunities and assess the market’s underlying potential.

Idiopathic Pulmonary Fibrosis: Overview

Idiopathic Pulmonary Fibrosis (IPF) is one of the most severe forms of interstitial pneumonia, characterized by chronic, progressive fibrosis, an inexorable decline in lung function, progressive respiratory failure, and a high mortality rate. The disorder’s classic symptoms include progressive dyspnea and a nonproductive cough. Typically, pulmonary function tests reveal restrictive impairment and decreased carbon monoxide diffusing capacity.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation

The Idiopathic Pulmonary Fibrosis report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:

  • Idiopathic Pulmonary Fibrosis Total Diagnosed Prevalent Cases

  • Idiopathic Pulmonary Fibrosis Gender-Specific Cases

  • Idiopathic Pulmonary Fibrosis Age-Specific Cases

  • Idiopathic Pulmonary Fibrosis Prevalent Population by Severity

Idiopathic Pulmonary Fibrosis Treatment Landscape

Non-pharmacological treatment modalities for Idiopathic Pulmonary Fibrosis include supplemental oxygen therapy, pulmonary rehabilitation, mechanical ventilation, and palliative care services. While the pharmacological treatment options for Idiopathic Pulmonary Fibrosis include Corticosteroids, immunosuppressive/cytotoxic agents (azathioprine, cyclophosphamide), and antifibrotic agents (e.g., colchicine or d-penicillamine) can be used alone or in combination. There are two antifibrotic agents that have been approved for Idiopathic Pulmonary Fibrosis treatment namely Esbriet and Ofev (tyrosine kinase inhibitors).

Idiopathic Pulmonary Fibrosis Market

  • The Idiopathic Pulmonary Fibrosis market size was found to be USD 2781.75 million in the 7MM in 2017.

  • The United States accounted for 79.2% of the overall IPF market size among the 7MM in 2017.

  • Among the EU countries, the UK accounted for the highest IPF market share while France had the lowest IPF market share.

  • The Idiopathic Pulmonary Fibrosis market size is anticipated to increase due to the launch of the upcoming therapies such as Pamrevlumab, RG6354, Ziritaxestat, and others during the forecast period (2020-30).

Get the detailed analysis of the upcoming therapies @ Idiopathic Pulmonary Fibrosis Drug Market

Idiopathic Pulmonary Fibrosis Pipeline Therapies and Key Companies 

  • Pamrevlumab: FibroGen

  • RG6354: Roche

  • Ziritaxestat: Galapagos NV

  • Tipelukast: MediciNova

  • GB 0139: Galecto Biotech

Idiopathic Pulmonary Fibrosis Market Drivers

  • Management of Comorbidities

  • Regulatory designations

  • Increase in the Geriatric population

  • Increased potential IPF therapies in the pipeline

Idiopathic Pulmonary Fibrosis Market Barriers

  • Unavailability of IPF cure

  • Poor IPF prognosis

  • Wait and Watch approach

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)

Study Period: 2017-30

Idiopathic Pulmonary Fibrosis Key Companies: FibroGen, Roche, Galapagos NV, MediciNova, Galecto Biotech, among others. 

Idiopathic Pulmonary Fibrosis Key Pipeline Therapies: Pamrevlumab, RG6354, Ziritaxestat, Tipelukast, GB 0139,and others.

Idiopathic Pulmonary Fibrosis Segmentation: By Geography, By Idiopathic Pulmonary Fibrosis therapies

Analysis: Comparative and conjoint analysis of Idiopathic Pulmonary Fibrosis emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

1.

Key Insights

2.

Executive summary

3.

Organizations

4.

Idiopathic Pulmonary Fibrosis (IPF): Market Overview at a Glance

5.

Idiopathic Pulmonary Fibrosis (IPF): Overview at a Glance

6.

Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

7.

Idiopathic Pulmonary Fibrosis Current Treatment Practices

8.

Idiopathic Pulmonary Fibrosis Unmet Needs

9.

Idiopathic Pulmonary Fibrosis Marketed Drugs

10.

Idiopathic Pulmonary Fibrosis Emerging Therapies

11.

Idiopathic Pulmonary Fibrosis (IPF): 7 Major Market Analysis

12.

Idiopathic Pulmonary Fibrosis Seven Major Market Outlook

13.

Idiopathic Pulmonary Fibrosis United States Market Size

14.

Idiopathic Pulmonary Fibrosis Market Drivers

15.

Idiopathic Pulmonary Fibrosis Market Barriers

16.

SWOT Analysis

17.

Idiopathic Pulmonary Fibrosis Market Access

18.

Case Study

19.

KOL’s Views

20.

Appendix

21.

DelveInsight Capabilities

22.

Disclaimer

23.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Interstitial Lung Disease Market

Get a comprehensive analysis of Interstitial Lung Disease pipeline therapies and key companies such as Roche, OncoArendi Pharmaceuticals, aTyr Pharma, Bristol Myers Squibb, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/